Could Spruce Biosciences finally change the Sanfilippo syndrome type B treatment landscape?
Spruce Biosciences’ MPS IIIB data raise a pivotal question: can tralesinidase alfa turn biomarker gains into disease-changing therapy?
Pharma & Biotech